Media for Stem Cell
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
Global Drugs for Oncology Market Research Report 2024
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Drugs for Oncology Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Oncology Market Perspective (2017-2028)
2.2 Drugs for Oncology Growth Trends by Region
2.2.1 Drugs for Oncology Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Drugs for Oncology Historic Market Size by Region (2017-2022)
2.2.3 Drugs for Oncology Forecasted Market Size by Region (2023-2028)
2.3 Drugs for Oncology Market Dynamics
2.3.1 Drugs for Oncology Industry Trends
2.3.2 Drugs for Oncology Market Drivers
2.3.3 Drugs for Oncology Market Challenges
2.3.4 Drugs for Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Oncology Players by Revenue
3.1.1 Global Top Drugs for Oncology Players by Revenue (2017-2022)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2017-2022)
3.2 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Oncology Revenue
3.4 Global Drugs for Oncology Market Concentration Ratio
3.4.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2021
3.5 Drugs for Oncology Key Players Head office and Area Served
3.6 Key Players Drugs for Oncology Product Solution and Service
3.7 Date of Enter into Drugs for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Oncology Breakdown Data by Type
4.1 Global Drugs for Oncology Historic Market Size by Type (2017-2022)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2023-2028)
5 Drugs for Oncology Breakdown Data by Application
5.1 Global Drugs for Oncology Historic Market Size by Application (2017-2022)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Drugs for Oncology Market Size (2017-2028)
6.2 North America Drugs for Oncology Market Size by Country (2017-2022)
6.3 North America Drugs for Oncology Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Drugs for Oncology Market Size (2017-2028)
7.2 Europe Drugs for Oncology Market Size by Country (2017-2022)
7.3 Europe Drugs for Oncology Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Oncology Market Size (2017-2028)
8.2 Asia-Pacific Drugs for Oncology Market Size by Country (2017-2022)
8.3 Asia-Pacific Drugs for Oncology Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Drugs for Oncology Market Size (2017-2028)
9.2 Latin America Drugs for Oncology Market Size by Country (2017-2022)
9.3 Latin America Drugs for Oncology Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Oncology Market Size (2017-2028)
10.2 Middle East & Africa Drugs for Oncology Market Size by Country (2017-2022)
10.3 Middle East & Africa Drugs for Oncology Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Drugs for Oncology Introduction
11.1.4 Roche Revenue in Drugs for Oncology Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Drugs for Oncology Introduction
11.2.4 Celgene Revenue in Drugs for Oncology Business (2017-2022)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Drugs for Oncology Introduction
11.3.4 Novartis Revenue in Drugs for Oncology Business (2017-2022)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Drugs for Oncology Introduction
11.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2017-2022)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Drugs for Oncology Introduction
11.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2017-2022)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Drugs for Oncology Introduction
11.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2017-2022)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Drugs for Oncology Introduction
11.8.4 Pfizer Revenue in Drugs for Oncology Business (2017-2022)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Drugs for Oncology Introduction
11.9.4 Amgen Revenue in Drugs for Oncology Business (2017-2022)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Drugs for Oncology Introduction
11.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2017-2022)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Drugs for Oncology Introduction
11.11.4 AbbVie Revenue in Drugs for Oncology Business (2017-2022)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Drugs for Oncology Introduction
11.12.4 Takeda Revenue in Drugs for Oncology Business (2017-2022)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Drugs for Oncology Introduction
11.13.4 Astellas Revenue in Drugs for Oncology Business (2017-2022)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Drugs for Oncology Introduction
11.14.4 Ipsen Revenue in Drugs for Oncology Business (2017-2022)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Drugs for Oncology Introduction
11.15.4 Sanofi Revenue in Drugs for Oncology Business (2017-2022)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Drugs for Oncology Introduction
11.16.4 Bayer Revenue in Drugs for Oncology Business (2017-2022)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Drugs for Oncology Introduction
11.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2017-2022)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Drugs for Oncology Introduction
11.18.4 Teva Revenue in Drugs for Oncology Business (2017-2022)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Drugs for Oncology Introduction
11.19.4 Otsuka Revenue in Drugs for Oncology Business (2017-2022)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Drugs for Oncology Introduction
11.20.4 Eisai Revenue in Drugs for Oncology Business (2017-2022)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Drugs for Oncology Introduction
11.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2017-2022)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Drugs for Oncology Introduction
11.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2017-2022)
11.22.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Immunotherapy (Biologic Therapy)
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Others
Table 7. Global Drugs for Oncology Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Drugs for Oncology Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Drugs for Oncology Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Drugs for Oncology Market Share by Region (2017-2022)
Table 11. Global Drugs for Oncology Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Drugs for Oncology Market Share by Region (2023-2028)
Table 13. Drugs for Oncology Market Trends
Table 14. Drugs for Oncology Market Drivers
Table 15. Drugs for Oncology Market Challenges
Table 16. Drugs for Oncology Market Restraints
Table 17. Global Drugs for Oncology Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Drugs for Oncology Market Share by Players (2017-2022)
Table 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2021)
Table 20. Ranking of Global Top Drugs for Oncology Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Drugs for Oncology Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Oncology Product Solution and Service
Table 24. Date of Enter into Drugs for Oncology Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Oncology Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Drugs for Oncology Revenue Market Share by Type (2017-2022)
Table 28. Global Drugs for Oncology Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Drugs for Oncology Revenue Market Share by Type (2023-2028)
Table 30. Global Drugs for Oncology Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Drugs for Oncology Revenue Market Share by Application (2017-2022)
Table 32. Global Drugs for Oncology Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Drugs for Oncology Revenue Market Share by Application (2023-2028)
Table 34. North America Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
Table 35. North America Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
Table 36. Europe Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
Table 37. Europe Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
Table 38. Asia-Pacific Drugs for Oncology Market Size by Region (2017-2022) & (US$ Million)
Table 39. Asia-Pacific Drugs for Oncology Market Size by Region (2023-2028) & (US$ Million)
Table 40. Latin America Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
Table 41. Latin America Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
Table 42. Middle East & Africa Drugs for Oncology Market Size by Country (2017-2022) & (US$ Million)
Table 43. Middle East & Africa Drugs for Oncology Market Size by Country (2023-2028) & (US$ Million)
Table 44. Roche Company Detail
Table 45. Roche Business Overview
Table 46. Roche Drugs for Oncology Product
Table 47. Roche Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 48. Roche Recent Development
Table 49. Celgene Company Detail
Table 50. Celgene Business Overview
Table 51. Celgene Drugs for Oncology Product
Table 52. Celgene Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 53. Celgene Recent Development
Table 54. Novartis Company Detail
Table 55. Novartis Business Overview
Table 56. Novartis Drugs for Oncology Product
Table 57. Novartis Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 58. Novartis Recent Development
Table 59. Bristol-Myers Squibb Company Detail
Table 60. Bristol-Myers Squibb Business Overview
Table 61. Bristol-Myers Squibb Drugs for Oncology Product
Table 62. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 63. Bristol-Myers Squibb Recent Development
Table 64. Johnson & Johnson Company Detail
Table 65. Johnson & Johnson Business Overview
Table 66. Johnson & Johnson Drugs for Oncology Product
Table 67. Johnson & Johnson Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 68. Johnson & Johnson Recent Development
Table 69. Merck & Co. Company Detail
Table 70. Merck & Co. Business Overview
Table 71. Merck & Co. Drugs for Oncology Product
Table 72. Merck & Co. Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 73. Merck & Co. Recent Development
Table 74. AstraZeneca Company Detail
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Drugs for Oncology Product
Table 77. AstraZeneca Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 78. AstraZeneca Recent Development
Table 79. Pfizer Company Detail
Table 80. Pfizer Business Overview
Table 81. Pfizer Drugs for Oncology Product
Table 82. Pfizer Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Amgen Company Detail
Table 85. Amgen Business Overview
Table 86. Amgen Drugs for Oncology Product
Table 87. Amgen Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 88. Amgen Recent Development
Table 89. Eli Lilly Company Detail
Table 90. Eli Lilly Business Overview
Table 91. Eli Lilly Drugs for Oncology Product
Table 92. Eli Lilly Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 93. Eli Lilly Recent Development
Table 94. AbbVie Company Detail
Table 95. AbbVie Business Overview
Table 96. AbbVie Drugs for OncologyProduct
Table 97. AbbVie Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 98. AbbVie Recent Development
Table 99. Takeda Company Detail
Table 100. Takeda Business Overview
Table 101. Takeda Drugs for OncologyProduct
Table 102. Takeda Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 103. Takeda Recent Development
Table 104. Astellas Company Detail
Table 105. Astellas Business Overview
Table 106. Astellas Drugs for OncologyProduct
Table 107. Astellas Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 108. Astellas Recent Development
Table 109. Ipsen Company Detail
Table 110. Ipsen Business Overview
Table 111. Ipsen Drugs for OncologyProduct
Table 112. Ipsen Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 113. Ipsen Recent Development
Table 114. Sanofi Company Detail
Table 115. Sanofi Business Overview
Table 116. Sanofi Drugs for OncologyProduct
Table 117. Sanofi Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 118. Sanofi Recent Development
Table 119. Bayer Company Detail
Table 120. Bayer Business Overview
Table 121. Bayer Drugs for OncologyProduct
Table 122. Bayer Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 123. Bayer Recent Development
Table 124. Biogen Idec Company Detail
Table 125. Biogen Idec Business Overview
Table 126. Biogen Idec Drugs for OncologyProduct
Table 127. Biogen Idec Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 128. Biogen Idec Recent Development
Table 129. Teva Company Detail
Table 130. Teva Business Overview
Table 131. Teva Drugs for OncologyProduct
Table 132. Teva Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 133. Teva Recent Development
Table 134. Otsuka Company Detail
Table 135. Otsuka Business Overview
Table 136. Otsuka Drugs for OncologyProduct
Table 137. Otsuka Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 138. Otsuka Recent Development
Table 139. Eisai Company Detail
Table 140. Eisai Business Overview
Table 141. Eisai Drugs for OncologyProduct
Table 142. Eisai Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 143. Eisai Recent Development
Table 144. Merck KGaA Company Detail
Table 145. Merck KGaA Business Overview
Table 146. Merck KGaA Drugs for OncologyProduct
Table 147. Merck KGaA Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 148. Merck KGaA Recent Development
Table 149. Gilead Sciences Company Detail
Table 150. Gilead Sciences Business Overview
Table 151. Gilead Sciences Drugs for OncologyProduct
Table 152. Gilead Sciences Revenue in Drugs for Oncology Business (2017-2022) & (US$ Million)
Table 153. Gilead Sciences Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Oncology Market Share by Type: 2021 VS 2028
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Immunotherapy (Biologic Therapy) Features
Figure 5. Hormonal Therapy Features
Figure 6. Others Features
Figure 7. Global Drugs for Oncology Market Share by Application in 2021 & 2028
Figure 8. Blood Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Gastrointestinal Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Respiratory/Lung Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Drugs for Oncology Report Years Considered
Figure 15. Global Drugs for Oncology Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 16. Global Drugs for Oncology Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 17. Global Drugs for Oncology Market Share by Region: 2021 VS 2028
Figure 18. Global Drugs for Oncology Market Share by Players in 2021
Figure 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2021
Figure 21. North America Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. North America Drugs for Oncology Market Share by Country (2017-2028)
Figure 23. United States Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Canada Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Europe Drugs for Oncology Market Share by Country (2017-2028)
Figure 27. Germany Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Drugs for Oncology Market Share by Region (2017-2028)
Figure 35. China Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Drugs for Oncology Market Share by Country (2017-2028)
Figure 43. Mexico Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Brazil Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Drugs for Oncology Market Share by Country (2017-2028)
Figure 47. Turkey Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Saudi Arabia Drugs for Oncology Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 50. Celgene Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 51. Novartis Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 53. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 54. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 55. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 56. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 57. Amgen Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 58. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 59. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 60. Takeda Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 61. Astellas Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 62. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 63. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 64. Bayer Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 65. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 66. Teva Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 67. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 68. Eisai Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 69. Merck KGaA Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 70. Gilead Sciences Revenue Growth Rate in Drugs for Oncology Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche Celgene Novartis Bristol-Myers Squibb Johnson & Johnson Merck & Co. AstraZeneca Pfizer Amgen Eli Lilly AbbVie Takeda Astellas Ipsen Sanofi Bayer Biogen Idec Teva Otsuka Eisai Merck KGaA Gilead Sciences